Updated:
Pharming Group
Pharming Group was founded in 1988 as a spin-out from Leiden University, initially focused on producing human therapeutic proteins in the milk of...
Pharming Group
Pharming Group was founded in 1988 as a spin-out from Leiden University, initially focused on producing human therapeutic proteins in the milk of transgenic rabbits. Sijmen de Vries took over as CEO in 2008, steering the company through a restructuring that pivoted it toward rare-disease commercial-stage operations. The firm is listed on Euronext Amsterdam and the Nasdaq. The company's commercial engine is Ruconest, a recombinant human C1 esterase inhibitor approved for acute hereditary angioedema attacks in the US, EU, and several other markets. Pharming generates revenue through direct sales in the US and select EU countries, supplemented by distribution partnerships in Asia, the Middle East, and Latin America. Its pipeline expands on the C1 inhibitor platform, targeting pre-eclampsia, acute kidney injury, and other conditions. The company also acquired leniolisib (Joenja) for activated PI3K delta syndrome, adding a second commercial rare-disease asset. Pharming employed approximately 500 professionals as of its 2023 annual report, with headquarters in Leiden and a US commercial hub in Warren, New Jersey. November 2024: Pharming reported a supply disruption for Joenja, its newly launched APDS treatment, slowing initial US commercial uptake (per the firm's third-quarter 2024 trading update). The company has not disclosed an investment portfolio or capital deployment figure typical of asset managers — it operates as an operating biotech company with a $1.2 billion market capitalization as of early 2024. Pharming's structural differentiator is its transgenic production platform — a rabbit-based recombinant manufacturing method that historically gave Ruconest a cost and purity advantage over plasma-derived competitors. The company has since diversified into small-molecule acquisitions, but its legacy C1 inhibitor franchise still anchors the P&L. Unlike a family office or fund, Pharming deploys capital as R&D and commercial spend, not as portfolio investments.
General information
Firm type
Asset Manager
Year founded
1988
AUM
Undisclosed
Location
Region
Europe
Country
Netherlands
City
Leiden
Corporate office
Leiden, Netherlands
Additional offices
Warren, NJ, United States
Principals
Sijmen de Vries
Chief Executive Officer
Sector focus
Frequently asked questions
What is Pharming Group's core business model?
Pharming is a publicly traded specialty pharmaceutical company focused on rare diseases. It commercializes Ruconest, a recombinant C1 esterase inhibitor for hereditary angioedema, directly in the US and through partners in Europe, Asia, and the Middle East. The company also launched Joenja (leniolisib) for activated PI3K delta syndrome. Pharming generates revenue from product sales, not management fees or carry, and does not function as a family office or asset manager.
Who controls investment and capital allocation decisions at Pharming?
As a publicly listed company with a supervisory board and management board, capital allocation decisions rest with CEO Sijmen de Vries and his executive team under board oversight. Pharming deploys capital into R&D, clinical trials, and commercial infrastructure. It does not manage third-party capital or operate a traditional investment portfolio.
Does Pharming participate in venture capital or biotech fund commitments?
Pharming has not publicly disclosed a venture investing mandate or LP fund-commitment program. Its external capital deployment has historically been limited to licensing transactions and outright acquisitions of clinical-stage assets, such as the 2019 acquisition of leniolisib from Novartis.
Where does Pharming generate the majority of its revenue geographically?
The United States accounts for the majority of Pharming's product revenue, driven by its direct sales force. European sales are conducted through a mix of direct selling and distribution partnerships. The company has been expanding into Asian and Latin American markets through local distribution agreements.
Is Pharming still using transgenic rabbit technology for manufacturing?
Pharming's original platform produced human therapeutic proteins in rabbit milk, and this remains the manufacturing method for Ruconest. However, the company has diversified its technology base — its second commercial product, Joenja, is an oral small-molecule drug acquired from Novartis. Future pipeline expansion may include both platform-derived and externally sourced assets.
How should an allocator understand Pharming's financial profile versus traditional investment firms?
Pharming is an operating biotech company, not a fund. It reported $245 million in revenue for 2023 with a market capitalization of roughly $1.2 billion as of early 2024. Allocators evaluating Pharming as a potential portfolio holding would treat it as a public-equity position in the specialty pharma or biotech sector, not as an allocation to an alternative-asset manager.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: